Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 252-258

  Kim, Hye Ryoun ^a   Lee, Jae Chol ^b   Kim, Young Chul ^c   Kim, Kyu Sik ^c   Oh, In Jae ^c   Lee, Sung Yong ^d   Jang, Tae Won ^e   Lee, Min Ki ^f   Shin, Kyeong Cheol ^g   Lee, Gwan Ho ^g   Ryu, Jeong Seon ^h   Jang, Seung Hoon ⁱ   Son, Ji Woong ^j   Lee, Jeong Eun ^k   Kim, Sun Young ^k   Kim, Hee Joung ^l   Lee, Kye Young ^l  

^a Korea Cancer Center Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Kosin University   (South Korea)

^f Pusan National University School of Medicine   (South Korea)

^g Yeungnam University College of Medicine   (South Korea)

^h Inha University School of Medicine   (South Korea)

ⁱ Hallym University   (South Korea)

^j Konyang University   (South Korea)

^k Chungnam National University   (South Korea)

^l Konkuk University School of Medicine   (South Korea)

more..

Author keywords

Acquired resistance; EGFR tyrosine kinase inhibitor; Failure togefitinib; Gefitinib; Non small cell lung cancer; Post progression survival (PPS)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER CENTER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE COURSE; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG LESION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TREATMENT RESPONSE; VERY ELDERLY;

ACQUIRED RESISTANCE; EGFR-TYROSINE KINASE INHIBITOR; FAILURE TOGEFITINIB; GEFITINIB; NON-SMALL CELL LUNG CANCER; POST-PROGRESSION SURVIVAL (PPS);

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84892845758     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.008     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
3. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
4. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
5. Kelly K., Crowley J., Bunn P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-3218.
6. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
7. Lynch T., Kim E. Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer 2005, 50(Suppl. 2):S25-S32.
8. Pennell N.A. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2011, 12:350-359.
9. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
10. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-2246.
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
12. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
13. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
14. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
15. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
16. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
17. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
18. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
19. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012, 44:852-860.
20. Nurwidya F., Takahashi F., Murakami A., Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012, 44:151-156.
21. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3:75ra26.
22. Segawa Y., Hotta K., Umemura S., Fujiwara Y., Shinkai T., Ueoka H., et al. Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer 2006, 107:1866-1872.
23. Lee Y.J., Choi H.J., Kim S.K., Chang J., Moon J.W., Park I.K., et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010, 116:1336-1343.
24. Kuo C.H., Lin S.M., Lee K.Y., Chung F.T., Hsieh M.H., Fang Y.F., et al. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 2010, 11:51-56.
25. Nishino K., Imamura F., Morita S., Mori M., Komuta K., Kijima T., et al. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer 2013, 82:299-304.
26. Yang J.J., Chen H.J., Yan H.H., Zhang X.C., Zhou Q., Su J., et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013, 79:33-39.
27. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Janne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
28. McKillop D., Hutchison M., Partridge E.A., Bushby N., Cooper C.M., Clarkson-Jones J.A., et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004, 34:917-934.
29. Jackman D.M., Holmes A.J., Lindeman N., Wen P.Y., Kesari S., Borras A.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24:4517-4520.
30. Morita S., Okamoto I., Kobayashi K., Yamazaki K., Asahina H., Inoue A., et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009, 15:4493-4498.